These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 17646236)

  • 1. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
    Merlo CA; Boyle MP; Diener-West M; Marshall BC; Goss CH; Lechtzin N
    Chest; 2007 Aug; 132(2):562-8. PubMed ID: 17646236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.
    Smith DJ; Ramsay KA; Yerkovich ST; Reid DW; Wainwright CE; Grimwood K; Bell SC; Kidd TJ
    Respirology; 2016 Feb; 21(2):329-37. PubMed ID: 26711802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.
    Ren CL; Konstan MW; Yegin A; Rasouliyan L; Trzaskoma B; Morgan WJ; Regelmann W;
    J Cyst Fibros; 2012 Jul; 11(4):293-9. PubMed ID: 22445849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
    Dasenbrook EC; Konstan MW; VanDevanter DR
    J Cyst Fibros; 2015 May; 14(3):370-5. PubMed ID: 25496726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
    Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
    J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F; Munck A; Kho P; Angyalosi G;
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
    Langan KM; Kotsimbos T; Peleg AY
    Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis.
    VanDyke RD; McPhail GL; Huang B; Fenchel MC; Amin RS; Carle AC; Chini BA; Seid M
    Ann Am Thorac Soc; 2013 Jun; 10(3):205-12. PubMed ID: 23802816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
    Moss RB
    Chest; 2002 Jan; 121(1):55-63. PubMed ID: 11796432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC; Brown R; Sacco P; Zhang J
    J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.